IATI · Aid

Sri Lanka: Health and population: development finance disbursed by Gavi, The Vaccine Alliance (IATI)

4.33Mcurrent USD · 2025+611.8% since 2015

Money paid out to the country by Gavi, The Vaccine Alliance for health and population. Summed by Interva from the disbursements Gavi, The Vaccine Alliance published to IATI, converted to US dollars at the World Bank's annual average exchange rate. Only spending assigned to a single country is included; regional spending is not. Development finance, grants and loans, concessional or not: not official development assistance (ODA). Funder types are kept apart and should not be added together: earmarked funds can appear under both a government and the multilateral it routes them through. Annual figures for Sri Lanka from 2002 to 2025.

20022025

Every year

YearValue (current USD)Note
20254,331,415.46
20245,532,634.03
20232,932,339.89
2022604,893.78
2021775,932.62
2020307,157.32
2019697,845.96
2018313,930.39
20171,786,322.71
2016-18,532.3
2015608,493.25
20141,036,168.81
20133,092,734.99
2012543,321
20113,698,872.61
20106,323,112.48
20093,270,586
20082,716,176.71
20073,835,652.13
2006371,614.82
20051,923,746.54
2004124,593.2
2003109,818
2002397,317

Source

Published by IATI, produced by International Aid Transparency Initiative. Licence: Open licences chosen by each IATI publisher. Retrieved 2026-11-15.

The dataset for every country, with quality and provenance →

Cite or download

IATI (2026). Health and population: development finance disbursed by Gavi, The Vaccine Alliance (IATI). Interva. https://interva.co/dataset/iati-disbursements-47122-health (accessed 2026-11-21). catalog snapshot 2026-11-15.

JSON, Sri LankaAPI and MCP

Health and population: development finance disbursed by Gavi, The Vaccine Alliance (IATI) in other countries

Rank Sri Lanka against its region, see where publishers disagree, or ask a question in plain words on the Interva desk.

Sri Lanka: Health and population: development finance disbursed by Gavi, The Vaccine Alliance (IATI) (2002–2025) · Interva